Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)

Journal of Clinical Medicine

Volumn 6, Issue 2, 2017, Pages

  Zufferey, Anne ^a,b   Kapur, Rick ^a,b,c   Semple, John W ^a,b,c,d,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Autoimmunity; B cells; Immune thrombocytopenia (ITP); Platelets; T cells

Indexed keywords

IMMUNOGLOBULIN; INDOLEAMINE 2,3 DIOXYGENASE; LIPOPOLYSACCHARIDE; RITUXIMAB;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; CELL PROLIFERATION; DISEASE SEVERITY; HEMOSTASIS; HUMAN; LYMPHOCYTE ACTIVATION; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PLATELET REACTIVITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 85067220122     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm6020016     Document Type: Review

References (216)

1. Rodeghiero, F.; Stasi, R.; Gernsheimer, T.; Michel, M.; Provan, D.; Arnold, D.M.; Bussel, J.B.; Cines, D.B.; Chong, B.H.; Cooper, N.; et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009, 113, 2386–2393.
2. Harrington, W.J.; Minnich, V.; Hollingsworth, J.W.; Moore, C.V. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J. Lab. Clin. Med. 1951, 38, 1–10.
3. Shulman, N.R.; Marder, V.J.; Weinrach, R.S. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann. N. Y. Acad. Sci. 1965, 124, 499–542.
4. Olsson, B.; Andersson, P.O.; Jernas, M.; Jacobsson, S.; Carlsson, B.; Carlsson, L.M.; Wadenvik, H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat. Med. 2003, 9, 1123–1124.
5. Khodadi, E.; Asnafi, A.A.; Shahrabi, S.; Shahjahani, M.; Saki, N. Bone marrow niche in immune thrombocytopenia: A focus on megakaryopoiesis. Ann. Hematol. 2016, 95, 1765–1776.
6. Dameshek, W.; Miller, E.B. The megakaryocytes in idiopathic thrombocytopenic purpura, a form of hypersplenism. Blood 1946, 1, 27–50.
7. Pisciotta, A.V.; Stefanini, M.; Dameshek, W. Studies on platelets. X. Morphologic characteristics of megakaryocytes by phase contrast microscopy in normals and in patients with idiopathic thrombocytopenic purpura. Blood 1953, 8, 703–723.
8. Neylon, A.J.; Saunders, P.W.; Howard, M.R.; Proctor, S.J.; Taylor, P.R.; Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients. Br. J. Haematol. 2003, 122, 966–974.
9. Perera, M.; Garrido, T. Advances in the pathophysiology of primary immune thrombocytopenia. Hematology 2016, 22, 41–53.
10. Schulze, H.; Gaedicke, G. Immune thrombocytopenia in children and adults: What’s the same, what’s different? Haematologica 2011, 96, 1739–1741.
11. Provan, D.; Newland, A.C. Current Management of Primary Immune Thrombocytopenia. Adv. Ther. 2015, 32, 875–887.
12. Zhang, W.; Nardi, M.A.; Borkowsky, W.; Li, Z.; Karpatkin, S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood 2009, 113, 4086–4093.
13. Wright, J.F.; Blanchette, V.S.; Wang, H.; Arya, N.; Petric, M.; Semple, J.W.; Chia, W.K.; Freedman, J. Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Br. J. Haematol. 1996, 95, 145–152.
14. Takahashi, T.; Yujiri, T.; Shinohara, K.; Inoue, Y.; Sato, Y.; Fujii, Y.; Okubo, M.; Zaitsu, Y.; Ariyoshi, K.; Nakamura, Y.; et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br. J. Haematol. 2004, 124, 91–96.
15. Li, Z.; Nardi, M.A.; Karpatkin, S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood 2005, 106, 572–576.
16. Cines, D.B.; Bussel, J.B.; Liebman, H.A.; Luning Prak, E.T. The ITP syndrome: Pathogenic and clinical diversity. Blood 2009, 113, 6511–6521.
17. Terrell, D.R.; Beebe, L.A.; Vesely, S.K.; Neas, B.R.; Segal, J.B.; George, J.N. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am. J. Hematol. 2010, 85, 174–180.
18. Frederiksen, H.; Schmidt, K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999, 94, 909–913.
19. Fogarty, P.F.; Segal, J.B. The epidemiology of immune thrombocytopenic purpura. Curr. Opin. Hematol. 2007, 14, 515–519.
20. Semple, J.W.; Italiano, J.E., Jr.; Freedman, J. Platelets and the immune continuum. Nat. Rev. Immunol. 2011, 11, 264–274.
21. Lazarus, A.H.; Semple, J.W.; Cines, D.B. Innate and adaptive immunity in immune thrombocytopenia. Semin. Hematol. 2013, 50, S68–S70.
22. Heitink-Polle, K.M.; Haverman, L.; Annink, K.V.; Schep, S.J.; de Haas, M.; Bruin, M.C. Health-related quality of life in children with newly diagnosed immune thrombocytopenia. Haematologica 2014, 99, 1525–1531.
23. George, J.N.; Mathias, S.D.; Go, R.S.; Guo, M.; Henry, D.H.; Lyons, R.; Redner, R.L.; Rice, L.; Schipperus, M.R. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: Results from two randomized, placebo-controlled trials. Br. J. Haematol. 2009, 144, 409–415.
24. Efficace, F.; Mandelli, F.; Fazi, P.; Santoro, C.; Gaidano, G.; Cottone, F.; Borchiellini, A.; Carpenedo, M.; Simula, M.P.; Di Giacomo, V.; et al. Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. Am. J. Hematol. 2016, 91, 995–1001.
25. Hill, Q.A.; Newland, A.C. Fatigue in immune thrombocytopenia. Br. J. Haematol. 2015, 170, 141–149.
26. Newton, J.L.; Reese, J.A.; Watson, S.I.; Vesely, S.K.; Bolton-Maggs, P.H.; George, J.N.; Terrell, D.R. Fatigue in adult patients with primary immune thrombocytopenia. Eur. J. Haematol. 2011, 86, 420–429.
27. Neunert, C.; Lim, W.; Crowther, M.; Cohen, A.; Solberg, L., Jr.; Crowther, M.A.; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117, 4190–4207.
28. Karpatkin, S.; Siskind, G.W. In vitro detection of platelet antibody in patients with idiopathic thrombocytopenic purpura and systemic lupus erythematosus. Blood 1969, 33, 795–812.
29. Karpatkin, S.; Strick, N.; Karpatkin, M.B.; Siskind, G.W. Cumulative experience in the detection of antiplatelet antibody in 234 patients with idiopathic thrombocytopenic purpura, systemic lupus erythematosus and other clinical disorders. Am. J. Med. 1972, 52, 776–785.
30. Lightsey, A.L., Jr.; McMillan, R.; Koenig, H.M.; Schanberger, J.E.; Lang, J.E. In vitro production of platelet-binding IgG in childhood idiopathic thrombocytopenic purpura. J. Pediatr. 1976, 88, 415–418.
31. He, R.; Reid, D.M.; Jones, C.E.; Shulman, N.R. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994, 83, 1024–1032.
32. Boylan, B.; Chen, H.; Rathore, V.; Paddock, C.; Salacz, M.; Friedman, K.D.; Curtis, B.R.; Stapleton, M.; Newman, D.K.; Kahn, M.L.; et al. Anti-GPVI-associated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood 2004, 104, 1350–1355.
33. Saleh, M.N.; Moore, D.L.; Lee, J.Y.; LoBuglio, A.F. Monocyte-platelet interaction in immune and nonimmune thrombocytopenia. Blood 1989, 74, 1328–1331.
34. + T cell-mediated responses that are differentially sensitive to therapy. Blood 2010, 115, 1247–1253.
35. Chang, M.; Nakagawa, P.A.; Williams, S.A.; Schwartz, M.R.; Imfeld, K.L.; Buzby, J.S.; Nugent, D.J. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003, 102, 887–895.
36. McMillan, R.; Wang, L.; Tomer, A.; Nichol, J.; Pistillo, J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004, 103, 1364–1369.
37. Aledort, L.M.; Hayward, C.P.; Chen, M.G.; Nichol, J.L.; Bussel, J.; Group, I.T.P.S. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am. J. Hematol. 2004, 76, 205–213.
38. Kaushansky, K. The molecular mechanisms that control thrombopoiesis. J. Clin. Investig. 2005, 115, 3339–3347.
39. Ballem, P.J.; Segal, G.M.; Stratton, J.R.; Gernsheimer, T.; Adamson, J.W.; Slichter, S.J. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J. Clin. Investig. 1987, 80, 33–40.
40. Emmons, R.V.; Reid, D.M.; Cohen, R.L.; Meng, G.; Young, N.S.; Dunbar, C.E.; Shulman, N.R. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996, 87, 4068–4071.
41. Semple, J.W.; Freedman, J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991, 78, 2619–2625.
42. Stasi, R. Immune thrombocytopenia: Pathophysiologic and clinical update. Semin. Thromb. Hemost. 2012, 38, 454–462.
43. Olsson, B.; Ridell, B.; Carlsson, L.; Jacobsson, S.; Wadenvik, H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008, 112, 1078–1084.
44. Houwerzijl, E.J.; Blom, N.R.; van der Want, J.J.; Esselink, M.T.; Koornstra, J.J.; Smit, J.W.; Louwes, H.; Vellenga, E.; de Wolf, J.T. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004, 103, 500–506.
45. Houwerzijl, E.J.; Blom, N.R.; van der Want, J.J.; Vellenga, E.; de Wolf, J.T. Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia 2006, 20, 1937–1942.
46. Semple, J.W.; Milev, Y.; Cosgrave, D.; Mody, M.; Hornstein, A.; Blanchette, V.; Freedman, J. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: Relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996, 87, 4245–4254.
47. Feng, X.; Scheinberg, P.; Samsel, L.; Rios, O.; Chen, J.; McCoy, J.P., Jr.; Ghanima, W.; Bussel, J.B.; Young, N.S. Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura. J. Thromb. Haemost. 2012, 10, 1616–1623.
48. Talaat, R.M.; Elmaghraby, A.M.; Barakat, S.S.; El-Shahat, M. Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP). Clin. Exp. Immunol. 2014, 176, 291–300.
49. Cuker, A.; Prak, E.T.; Cines, D.B. Can immune thrombocytopenia be cured with medical therapy? Semin. Thromb. Hemost. 2015, 41, 395–404.
50. Nomura, S. Advances in Diagnosis and Treatments for Immune Thrombocytopenia. Clin. Med. Insights Blood Disord. 2016, 9, 15–22.
51. Nielsen, O.H.; Tuckuviene, R.; Nielsen, K.R.; Rosthoj, S. Flow cytometric measurement of platelet-associated immunoglobulin in children with newly diagnosed Immune Thrombocytopenia. Eur. J. Haematol. 2016, 96, 397–403.
52. Arnason, J.E.; Campigotto, F.; Neuberg, D.; Bussel, J.B. Abnormalities in IgA and IgM are associated with treatment-resistant ITP. Blood 2012, 119, 5016–5020.
53. Cines, D.B.; Cuker, A.; Semple, J.W. Pathogenesis of immune thrombocytopenia. Presse Med. 2014, 43, e49–e59.
54. Zhang, H.Y.; Hou, M.; Zhang, X.H.; Guan, X.H.; Sun, G.Z. The diagnostic value of platelet glycoprotein-specific autoantibody detection in idiopathic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2004, 12, 204–206.
55. Fujisawa, K.; O’Toole, T.E.; Tani, P.; Loftus, J.C.; Plow, E.F.; Ginsberg, M.H.; McMillan, R. Autoantibodies to the presumptive cytoplasmic domain of platelet glycoprotein IIIa in patients with chronic immune thrombocytopenic purpura. Blood 1991, 77, 2207–2213.
56. Kuwana, M.; Kaburaki, J.; Ikeda, Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J. Clin. Investig. 1998, 102, 1393–1402.
57. Jin, C.Q.; Dong, H.X.; Cheng, P.P.; Zhou, J.W.; Zheng, B.Y.; Liu, F. Antioxidant status and oxidative stress in patients with chronic ITP. Scand. J. Immunol. 2013, 77, 482–487.
58. Nieswandt, B.; Bergmeier, W.; Rackebrandt, K.; Gessner, J.E.; Zirngibl, H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 2000, 96, 2520–2527.
59. Webster, M.L.; Sayeh, E.; Crow, M.; Chen, P.; Nieswandt, B.; Freedman, J.; Ni, H. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 2006, 108, 943–946.
60. Mason, K.D.; Carpinelli, M.R.; Fletcher, J.I.; Collinge, J.E.; Hilton, A.A.; Ellis, S.; Kelly, P.N.; Ekert, P.G.; Metcalf, D.; Roberts, A.W.; et al. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128, 1173–1186.
61. Leytin, V.; Mykhaylov, S.; Starkey, A.F.; Allen, D.J.; Lau, H.; Ni, H.; Semple, J.W.; Lazarus, A.H.; Freedman, J. Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br. J. Haematol. 2006, 133, 78–82.
62. Deng, G.; Yu, S.; Li, Q.; He, Y.; Liang, W.; Yu, L.; Xu, D. Investigation of platelet apoptosis in adult patients with chronic immune thrombocytopenia. Hematology 2016, 1–7.
63. Urbanus, R.T.; van der Wal, D.E.; Koekman, C.A.; Huisman, A.; van den Heuvel, D.J.; Gerritsen, H.C.; Deckmyn, H.; Akkerman, J.N.; Schutgens, R.E.G.; Gitz, E. Patient autoantibodies induce platelet destruction signals via raft-associated glycoprotein Ibalpha and Fc RIIa in immune thrombocytopenia. Haematologica 2013, 98, e70–e72.
64. Kapur, R.; Heitink-Polle, K.M.; Porcelijn, L.; Bentlage, A.E.; Bruin, M.C.; Visser, R.; Roos, D.; Schasfoort, R.B.; de Haas, M.; van der Schoot, C.E.; et al. C-reactive protein enhances IgG-mediated phagocyte responses and thrombocytopenia. Blood 2015, 125, 1793–1802.
65. Weiss, H.J.; Rosove, M.H.; Lages, B.A.; Kaplan, K.L. Acquired storage pool deficiency with increased platelet-associated IgG. Report of five cases. Am. J. Med. 1980, 69, 711–717.
66. Sarpatwari, A.; Bennett, D.; Logie, J.W.; Shukla, A.; Beach, K.J.; Newland, A.C.; Sanderson, S.; Proven, D. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010, 95, 1167–1175.
67. Severinsen, M.T.; Engebjerg, M.C.; Farkas, D.K.; Jensen, A.O.; Norgaard, M.; Zhao, S.; Sorensen, H.T. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: A Danish population-based cohort study. Br. J. Haematol. 2011, 152, 360–362.
68. Norgaard, M.; Severinsen, M.T.; Lund Maegbaek, M.; Jensen, A.O.; Cha, S.; Sorensen, H.T. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: A Danish population-based cohort study. Br. J. Haematol. 2012, 159, 109–111.
69. Jy, W.; Horstman, L.L.; Arce, M.; Ahn, Y.S. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J. Lab. Clin. Med. 1992, 119, 334–345.
70. Alvarez-Roman, M.T.; Fernandez-Bello, I.; Jimenez-Yuste, V.; Martin-Salces, M.; Arias-Salgado, E.G.; Rivas Pollmar, M.I.; Justo Sanz, R.; Butta, N.V. Procoagulant profile in patients with immune thrombocytopenia. Br. J. Haematol. 2016, 175, 925–934.
71. Yanabu, M.; Nomura, S.; Fukuroi, T.; Suzuki, M.; Kawakatsu, T.; Kido, H.; Yamaguchi, K. Platelet activation induced by an antiplatelet autoantibody against CD9 antigen and its inhibition by another autoantibody in immune thrombocytopenic purpura. Br. J. Haematol. 1993, 84, 694–701.
72. Chen, J.F.; Yang, L.H.; Chang, L.X.; Feng, J.J.; Liu, J.Q. The clinical significance of circulating B cells secreting anti-glycoprotein IIb/IIIa antibody and platelet glycoprotein IIb/IIIa in patients with primary immune thrombocytopenia. Hematology 2012, 17, 283–290.
73. Emmerich, F.; Bal, G.; Barakat, A.; Milz, J.; Muhle, C.; Martinez-Gamboa, L.; Dorner, T.; Salama, A. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br. J. Haematol. 2007, 136, 309–314.
74. Zhou, Z.H.; Zhuang, L.; Li, X.Y.; Li, J.; Luo, S.K. The role of B cell-activating factor secreted by peripheral blood monocyte-derived dendritic cell in chronic idiopathic thrombocytopenic purpura. Zhonghua Xue Ye Xue Za Zhi 2010, 31, 599–602.
75. Yang, Q.; Xu, S.; Li, X.; Wang, B.; Wang, X.; Ma, D.; Yang, L.; Peng, J.; Hou, M. Pathway of Toll-like receptor 7/B cell activating factor/B cell activating factor receptor plays a role in immune thrombocytopenia in vivo. PLoS ONE 2011, 6, e22708.
76. Yu, H.; Liu, Y.; Han, J.; Yang, Z.; Sheng, W.; Dai, H.; Wang, Y.; Xia, T.; Hou, M. TLR7 regulates dendritic cell-dependent B-cell responses through BlyS in immune thrombocytopenic purpura. Eur. J. Haematol. 2011, 86, 67–74.
77. Olsson, B.; Ridell, B.; Jernas, M.; Wadenvik, H. Increased number of B-cells in the red pulp of the spleen in ITP. Ann. Hematol. 2012, 91, 271–277.
78. Daridon, C.; Loddenkemper, C.; Spieckermann, S.; Kuhl, A.A.; Salama, A.; Burmester, G.R.; Lipsky, P.E.; Dörner, T. Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia. Blood 2012, 120, 5021–5031.
79. Li, X.; Zhong, H.; Bao, W.; Boulad, N.; Evangelista, J.; Haider, M.A.; Bussel, J.; Yazdanbakhsh, K. Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood 2012, 120, 3318–3325.
80. Semple, J.W. Bregging rights in ITP. Blood 2012, 120, 3169.
81. + regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin. Hematol. 2013, 50, S43–S49.
82. Mauri, C.; Bosma, A. Immune regulatory function of B cells. Annu. Rev. Immunol. 2012, 30, 221–241.
83. Aslam, R.; Segel, G.B.; Burack, R.; Spence, S.A.; Speck, E.R.; Guo, L.; Semple, J.W. Splenic lymphocyte subtypes in immune thrombocytopenia: Increased presence of a subtype of B-regulatory cells. Br. J. Haematol. 2016, 173, 159–160.
84. Jansen, P.H.; Renier, W.O.; de Vaan, G.; Reekers, P.; Vingerhoets, D.M.; Gabreels, F.J. Effect of thymectomy on myasthenia gravis and autoimmune thrombocytopenic purpura in a 13-year-old girl. Eur. J. Pediatr. 1987, 146, 587–589.
85. Stuart, M.J.; Tomar, R.H.; Miller, M.L.; Davey, F.R. Chronic idiopathic thrombocytopenic purpura. A familial immunodeficiency syndrome? JAMA 1978, 239, 939–942.
86. Waters, A.H. Autoimmune thrombocytopenia: Clinical aspects. Semin. Hematol. 1992, 29, 18–25.
87. +) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. Sci. Rep. 2016, 6, 27445.
88. Zhang, F.; Chu, X.; Wang, L.; Zhu, Y.; Li, L.; Ma, D.; Peng, J.; Hou, M. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur. J. Haematol. 2006, 76, 427–431.
89. Zhao, C.; Li, X.; Zhang, F.; Wang, L.; Peng, J.; Hou, M. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008, 93, 1428–1430.
90. Stasi, R.; Cooper, N.; Del Poeta, G.; Stipa, E.; Laura Evangelista, M.; Abruzzese, E.; Amadori, S. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008, 112, 1147–1150.
91. Bao, W.; Bussel, J.B.; Heck, S.; He, W.; Karpoff, M.; Boulad, N.; Yazdanbakhsh, K. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010, 116, 4639–4645.
92. Audia, S.; Samson, M.; Guy, J.; Janikashvili, N.; Fraszczak, J.; Trad, M.; Ciudad, M.; Leguy, V.; Berthier, S.; Petrella, T.; et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood 2011, 118, 4394–4400.
93. Li, Z.; Mou, W.; Lu, G.; Cao, J.; He, X.; Pan, X.; Xu, K. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int. J. Hematol. 2011, 93, 91–98.
94. Li, H.; Ge, J.; Zhao, H.; Du, W.; Xu, J.; Sui, T.; Ma, L.; Zhou, Z.; Qi, A.; Yang, R. Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with idiopathic thrombocytopenic purpura in a Chinese population. Platelets 2011, 22, 39–44.
95. + regulatory T cells and transforming growth factor-beta1 in childhood immune thrombocytopenic purpura. Egypt. J. Immunol. 2006, 13, 173–187.
96. + regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur. J. Haematol. 2007, 79, 310–316.
97. + regulatory T cells in patients with idiopathic thrombocytopenic purpura. Zhonghua Xue Ye Xue Za Zhi 2007, 28, 184–188.
98. + T cells in patients with idiopathic thrombocytopenic purpura. Thromb. Res. 2007, 120, 187–193.
99. Zhang, J.; Ma, D.; Zhu, X.; Qu, X.; Ji, C.; Hou, M. Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica 2009, 94, 1326–1329.
100. +)CD25(−) cells in patients with idiopathic thrombocytopenic purpura. Blood 2009, 113, 2568–2577.
101. + regulatory T cells and TGF-ss1 in patient with idiopathic thrombocytopenic purpura. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2010, 26, 895–897.
102. +) T cells in chronic idiopathic thrombocytopenic purpura. Zhonghua Nei Ke Za Zhi 2010, 49, 213–216.
103. + T cells in children with idiopathic thrombocytopenic purpura. J. Pediatr. Hematol. Oncol. 2011, 33, 81–85.
104. Wang, X.P.; Qiu, Y.S.; Hao, G.P.; Zhu, L. Levels of regulatory T cells in peripheral blood of children with idiopathic thrombocytopenic purpura. Zhongguo Dang Dai Er Ke Za Zhi 2011, 13, 282–284.
105. Park, S.H.; Kim, J.Y.; Kim, S.K.; Choe, J.Y.; Kim, S.G.; Ryoo, H.M. Regulatory T-cells in systemic lupus erythematosus-associated thrombocytopenia: A comparison with idiopathic thrombocytopenic purpura. Lupus 2010, 19, 888–889.
106. Ji, L.; Zhan, Y.; Hua, F.; Li, F.; Zou, S.; Wang, W.; Song, D. The ratio of Treg/Th17 cells correlates with the disease activity of primary immune thrombocytopenia. PLoS ONE 2012, 7, e50909.
107. Olsson, B.; Andersson, P.O.; Jacobsson, S.; Carlsson, L.; Wadenvik, H. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb. Haemost. 2005, 93, 139–144.
108. Gratz, I.K.; Rosenblum, M.D.; Abbas, A.K. The life of regulatory T cells. Ann. N. Y. Acad. Sci. 2013, 1283, 8–12.
109. + regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010, 10, 490–500.
110. Semple, J.W.; Provan, D.; Garvey, M.B.; Freedman, J. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr. Opin. Hematol. 2010, 17, 590–595.
111. Kuwana, M.; Ikeda, Y. The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int. J. Hematol. 2005, 81, 106–112.
112. + regulatory T cells in autoimmunity: Immunopathogenesis and therapeutic implications. Am. J. Pathol. 2009, 174, 1575–1587.
113. +) regulatory T cells in idiopathic thrombocytopenic purpura. Eur. J. Haematol. 2007, 78, 139–143.
114. Yu, J.; Heck, S.; Patel, V.; Levan, J.; Yu, Y.; Bussel, J.B.; Yazdanbakhsh, K. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008, 112, 1325–1328.
115. + T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood 2012, 120, 2127–2132.
116. Catani, L.; Sollazzo, D.; Trabanelli, S.; Curti, A.; Evangelisti, C.; Polverelli, N.; Palandri, F. Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. Ann. Hematol. 2013, 92, 67–78.
117. Yang, Y.; Zhang, X.; Zhang, D.; Li, H.; Ma, L.; Xuan, M.; Wang, H.; Yang, R. Abnormal Distribution and Function of Monocyte Subsets in Patients With Primary Immune Thrombocytopenia. Clin. Appl. Thromb. Hemost. 2016.
118. + monocytes control T-cell subset development in immune thrombocytopenia. Blood 2012, 120, 3326–3335.
119. Ware, R.E.; Howard, T.A. Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura. Blood 1993, 82, 2137–2142.
120. Filion, M.C.; Bradley, A.J.; Devine, D.V.; Decary, F.; Chartrand, P. Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy. Eur. J. Immunol. 1995, 25, 3123–3127.
121. Coopamah, M.D.; Garvey, M.B.; Freedman, J.; Semple, J.W. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update. Transfus. Med. Rev. 2003, 17, 69–80.
122. Eyerich, S.; Eyerich, K.; Pennino, D.; Carbone, T.; Nasorri, F.; Pallotta, S.; Cianfarani, F.; Odorisio, T.; Traidl-Hoffmann, C.; Behrendt, H. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Investig. 2009, 119, 3573–3585.
123. Cao, J.; Chen, C.; Li, L.; Zeng, L.; Li, Z.; Yan, Z.; Chen, W.; Cheng, H.; Sang, W.; Xu, K. Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia. J. Clin. Immunol. 2012, 32, 523–529.
124. Cao, J.; Chen, C.; Zeng, L.; Li, L.; Li, X.; Li, Z.; Xu, K. Elevated plasma IL-22 levels correlated with Th1 and Th22 cells in patients with immune thrombocytopenia. Clin. Immunol. 2011, 141, 121–123.
125. Hu, Y.; Li, H.; Zhang, L.; Shan, B.; Xu, X.; Li, H.; Liu, X.; Xu, S.; Yu, S.; Ma, D.; et al. Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia. Hum. Immunol. 2012, 73, 629–635.
126. Liu, L.M.; Zhang, X.X.; Zhao, G.S.; Si, Y.J.; Lin, G.Q.; Zhang, Y.M.; He, G.S.; Wu, D.P. Change of Th22 cells in peripheral blood of patients with primary immune thrombocytopenia and clinical implication. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012, 28, 1314–1316.
127. Guo, N.H.; Shi, Q.Z.; Hua, J.Y.; Li, Z.J.; Li, J.; He, W.F.; Wu, Q. Expression of regulatory T cells and Th17 cells in idiopathic thrombocytopenic purpura and its significance. Zhonghua Xue Ye Xue Za Zhi 2010, 31, 610–612.
128. Hu, Y.; Ma, D.X.; Shan, N.N.; Zhu, Y.Y.; Liu, X.G.; Zhang, L.; Yu, S. Increased number of Tc17 and correlation with Th17 cells in patients with immune thrombocytopenia. PLoS ONE 2011, 6, e26522.
129. Rocha, A.M.; Souza, C.; Rocha, G.A.; de Melo, F.F.; Clementino, N.C.; Marino, M.C.; Bozzi, A.; Silva, M.L.; Martins Filho, O.A.; Queiroz, D.M. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica 2011, 96, 1560–1564.
130. Duan, X.J.; Yang, L.H.; Zhang, L.; Ren, F.G.; Zhang, R.J.; Chen, J.F.; Qin, X.Y.; Liang, H.Z. Expressions of Th17 cells and interleukin 17 in patients with primary immune thrombocytopenia and their clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012, 20, 1154–1157.
131. Yoh, K.; Morito, N.; Ojima, M.; Shibuya, K.; Yamashita, Y.; Morishima, Y.; Ishii, Y.; Kusakabe, M.; Nishikii, H.; Fujita, A.; et al. Overexpression of RORgammat under control of the CD2 promoter induces polyclonal plasmacytosis and autoantibody production in transgenic mice. Eur. J. Immunol. 2012, 42, 1999–2009.
132. Baeten, D.L.; Kuchroo, V.K. How Cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases. Nat. Med. 2013, 19, 824–825.
133. Guo, Z.X.; Chen, Z.P.; Zheng, C.L.; Jia, H.R.; Ge, J.; Gu, D.S.; Du, W.T.; Wang, X.Y.; Zhao, H.F.; Yang, R.C. The role of Th17 cells in adult patients with chronic idiopathic thrombocytopenic purpura. Eur. J. Haematol. 2009, 82, 488–489.
134. Ma, D.; Zhu, X.; Zhao, P.; Zhao, C.; Li, X.; Zhu, Y.; Li, L. Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Ann. Hematol. 2008, 87, 899–904.
135. + Th17 cells are not increased in immune thrombocytopenia. Haematologica 2011, 96, 632–634.
136. Rock, K.L.; Benacerraf, B.; Abbas, A.K. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J. Exp. Med. 1984, 160, 1102–1113.
137. Unanue, E.R. Antigen-presenting function of the macrophage. Annu. Rev. Immunol. 1984, 2, 395–428.
138. Amodio, G.; Gregori, S. Dendritic cells a double-edge sword in autoimmune responses. Front. Immunol. 2012, 3, 233.
139. Watts, C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 1997, 15, 821–850.
140. Banchereau, J.; Briere, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y.J.; Pulendran, B. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18, 767–811.
141. Chaplin, D.D. Overview of the immune response. J. Allergy Clin. Immunol. 2010, 125, S3–23.
142. Hughes, C.E.; Benson, R.A.; Bedaj, M.; Maffia, P. Antigen-Presenting Cells and Antigen Presentation in Tertiary Lymphoid Organs. Front. Immunol. 2016, 7, 481.
143. Coutant, F.; Miossec, P. Altered dendritic cell functions in autoimmune diseases: Distinct and overlapping profiles. Nat. Rev. Rheumatol. 2016, 12, 703–715.
144. Catani, L.; Fagioli, M.E.; Tazzari, P.L.; Ricci, F.; Curti, A.; Rovito, M.; Preda, P. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp. Hematol. 2006, 34, 879–887.
145. Saito, A.; Yokohama, A.; Osaki, Y.; Ogawa, Y.; Nakahashi, H.; Toyama, K.; Mitsui, T.; Hashimoto, Y.; Koiso, H.; Uchiumi, H.; et al. Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori-associated immune thrombocytopenia. Eur. J. Haematol. 2012, 88, 340–349.
146. Swiecki, M.; Colonna, M. The multifaceted biology of plasmacytoid dendritic cells. Nat. Rev. Immunol. 2015, 15, 471–485.
147. Panda, S.K.; Kolbeck, R.; Sanjuan, M.A. Plasmacytoid dendritic cells in autoimmunity. Curr. Opin. Immunol. 2016, 44, 20–25.
148. Andonegui, G.; Kerfoot, S.M.; McNagny, K.; Ebbert, K.V.; Patel, K.D.; Kubes, P. Platelets express functional Toll-like receptor-4. Blood 2005, 106, 2417–2423.
149. Aslam, R.; Speck, E.R.; Kim, M.; Crow, A.R.; Bang, K.W.; Nestel, F.P.; Ni, H.; Lazarus, A.H.; Freedman, J.; Semple, J.W. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006, 107, 637–641.
150. Semple, J.W.; Aslam, R.; Kim, M.; Speck, E.R.; Freedman, J. Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG-opsonized platelets. Blood 2007, 109, 4803–4805.
151. Machlus, K.R.; Thon, J.N.; Italiano, J.E., Jr. Interpreting the developmental dance of the megakaryocyte: A review of the cellular and molecular processes mediating platelet formation. Br. J. Haematol. 2014, 165, 227–236.
152. Stahl, C.P.; Zucker-Franklin, D.; McDonald, T.P. Incomplete antigenic cross-reactivity between platelets and megakaryocytes: Relevance to ITP. Blood 1986, 67, 421–428.
153. Nugent, D.; McMillan, R.; Nichol, J.L.; Slichter, S.J. Pathogenesis of chronic immune thrombocytopenia: Increased platelet destruction and/or decreased platelet production. Br. J. Haematol. 2009, 146, 585–596.
154. + cells. Blood 1998, 91, 830–843.
155. Hou, M.; Andersson, P.O.; Stockelberg, D.; Mellqvist, U.H.; Ridell, B.; Wadenvik, H. Plasma thrombopoietin levels in thrombocytopenic states: Implication for a regulatory role of bone marrow megakaryocytes. Br. J. Haematol. 1998, 101, 420–424.
156. Iraqi, M.; Perdomo, J.; Yan, F.; Choi, P.Y.; Chong, B.H. Immune thrombocytopenia: Antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Haematologica 2015, 100, 623–632.
157. Zhang, D.; Li, H.; Ma, L.; Zhang, X.; Xue, F.; Zhou, Z.; Chi, Y. The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia. Autoimmunity 2014, 47, 519–529.
158. Bruns, I.; Lucas, D.; Pinho, S.; Ahmed, J.; Lambert, M.P.; Kunisaki, Y.; Scheiermann, C.; Schiff, L.; Poncz, M.; Bergman, A.; et al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat. Med. 2014, 20, 1315–1320.
159. Nakamura-Ishizu, A.; Takubo, K.; Kobayashi, H.; Suzuki-Inoue, K.; Suda, T. CLEC-2 in megakaryocytes is critical for maintenance of hematopoietic stem cells in the bone marrow. J. Exp. Med. 2015, 212, 2133–2146.
160. Malara, A.; Abbonante, V.; Di Buduo, C.A.; Tozzi, L.; Currao, M.; Balduini, A. The secret life of a megakaryocyte: Emerging roles in bone marrow homeostasis control. Cell. Mol. Life Sci. 2015, 72, 1517–1536.
161. Winter, O.; Moser, K.; Mohr, E.; Zotos, D.; Kaminski, H.; Szyska, M.; Roth, K.; Wong, D.M.; Dame, C.; Tarlinton, D.M.; et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood 2010, 116, 1867–1875.
162. Uccelli, A.; Moretta, L.; Pistoia, V. Immunoregulatory function of mesenchymal stem cells. Eur. J. Immunol. 2006, 36, 2566–2573.
163. Kong, Y.; Hu, Y.; Zhang, X.H.; Wang, Y.Z.; Mo, X.D.; Zhang, Y.Y.; Wang, Y.; Han, W.; Xu, L.P.; Chang, Y.J.; et al. Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2014, 20, 1190–1197.
164. Kojouri, K.; Vesely, S.K.; Terrell, D.R.; George, J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004, 104, 2623–2634.
165. Rodeghiero, F.; Ruggeri, M. Short- and long-term risks of splenectomy for benign haematological disorders: Should we revisit the indications? Br. J. Haematol. 2012, 158, 16–29.
166. Lazarus, A.H. Monoclonal versus polyclonal anti-D in the treatment of ITP. Expert Opin. Biol. Ther. 2013, 13, 1353–1356.
167. Crow, A.R.; Lazarus, A.H. Mechanistic properties of intravenous immunoglobulin in murine immune thrombocytopenia: Support for FcgammaRIIB falls by the wayside. Semin. Hematol. 2016, 53, S20–S22.
168. Provan, D.; Stasi, R.; Newland, A.C.; Blanchette, V.S.; Bolton-Maggs, P.; Bussel, J.B.; Chong, B.H. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115, 168–186.
169. Bussel, J.B.; Lee, C.S.; Seery, C.; Imahiyerobo, A.A.; Thompson, M.V.; Catellier, D.; Turenne, I.G. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica 2014, 99, 1264–1271.
170. Zaja, F.; Baccarani, M.; Mazza, P.; Bocchia, M.; Gugliotta, L.; Zaccaria, A.; Vianelli, N.; Defina, M.; Tieghi, A.; Amadori, S.; et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010, 115, 2755–2762.
171. McHeyzer-Williams, L.J.; McHeyzer-Williams, M.G. Antigen-specific memory B cell development. Annu. Rev. Immunol. 2005, 23, 487–513.
172. Grimaldi, D.; Canoui-Poitrine, F.; Croisille, L.; Lee, K.; Roudot-Thoraval, F.; Languille, L.; Khellaf, M. Antiplatelet antibodies detected by the MAIPA assay in newly diagnosed immune thrombocytopenia are associated with chronic outcome and higher risk of bleeding. Ann. Hematol. 2014, 93, 309–315.
173. Cole, T.J. Glucocorticoid action and the development of selective glucocorticoid receptor ligands. Biotechnol. Annu. Rev. 2006, 12, 269–300.
174. Li, J.; Wang, Z.; Dai, L.; Cao, L.; Su, J.; Zhu, M.; Yu, Z.; Bai, X.; Ruan, C. Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia. Clin. Dev. Immunol. 2013, 2013, 548085.
175. Li, J.; Wang, Z.; Hu, S.; Zhao, X.; Cao, L. Correction of abnormal T cell subsets by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. Immunol. Lett. 2013, 154, 42–48.
176. Guo, X.H.; Zhao, F.; Shi, W.; Ma, X.M.; Xu, Q.; Patiguli, A.B.; Halida, Y.S. Detection and clinical significance of Th1/Th2 cytokines in patients with idiopathic thrombocytopenic purpura. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012, 28, 1185–1187.
177. Clynes, R. Immune complexes as therapy for autoimmunity. J. Clin. Investig. 2005, 115, 25–27.
178. Nagelkerke, S.Q.; Kuijpers, T.W. Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all? Front. Immunol. 2014, 5, 674.
179. Gilardin, L.; Bayry, J.; Kaveri, S.V. Intravenous immunoglobulin as clinical immune-modulating therapy. CMAJ 2015, 187, 257–264.
180. Park-Min, K.H.; Serbina, N.V.; Yang, W.; Ma, X.; Krystal, G.; Neel, B.G.; Nutt, S.L.; Hu, X.; Ivashkiv, L.B. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007, 26, 67–78.
181. Pang, S.J.; Lazarus, A.H. Mechanisms of platelet recovery in ITP associated with therapy. Ann. Hematol. 2010, 89, 31–35.
182. Crow, A.R.; Lazarus, A.H. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-D immunoglobulin in the amelioration of immune thrombocytopenic purpura: What do we really know? Transfus. Med. Rev. 2008, 22, 103–116.
183. Fehr, J.; Hofmann, V.; Kappeler, U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N. Engl. J. Med. 1982, 306, 1254–1258.
184. Berchtold, P.; Dale, G.L.; Tani, P.; McMillan, R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989, 74, 2414–2417.
185. Hansen, R.J.; Balthasar, J.P. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb. Haemost. 2002, 88, 898–899.
186. Bayry, J.; Lacroix-Desmazes, S.; Carbonneil, C.; Misra, N.; Donkova, V.; Pashov, A.; Chevailler, A.; Mouthon, L.; Weill, B.; Bruneval, P.; et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003, 101, 758–765.
187. Siragam, V.; Crow, A.R.; Brinc, D.; Song, S.; Freedman, J.; Lazarus, A.H. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat. Med. 2006, 12, 688–692.
188. Anthony, R.M.; Wermeling, F.; Karlsson, M.C.; Ravetch, J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. USA 2008, 105, 19571–19578.
189. o(D)). Blut 1984, 49, 29–35.
190. Song, S.; Crow, A.R.; Siragam, V.; Freedman, J.; Lazarus, A.H. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 2005, 105, 1546–1548.
191. Ambriz-Fernandez, R.; Martinez-Murillo, C.; Quintana-Gonzalez, S.; Collazo-Jaloma, J.; Bautista-Juarez, J. Fc receptor blockade in patients with refractory chronic immune thrombocytopenic purpura with anti-D IgG. Arch. Med. Res. 2002, 33, 536–540.
192. Boughton, B.J.; Cooke, R.M.; Smith, N.A.; Simpson, A.W. Autoimmune thrombocytopenia: Anti-glycoprotein IIb/IIIa auto antibodies are reduced after human anti-D immunoglobulin treatment. Autoimmunity 1994, 18, 141–144.
193. Kuwana, M.; Okazaki, Y.; Kaburaki, J.; Kawakami, Y.; Ikeda, Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J. Immunol. 2002, 168, 3675–3682.
194. Knobl, P. Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. Semin. Thromb. Hemost. 2014, 40, 493–502.
195. Guan, Y.; Wang, S.; Xue, F.; Liu, X.; Zhang, L.; Li, H.; Yang, R. Long-term results of splenectomy in adult chronic immune thrombocytopenia. Eur. J. Haematol. 2016.
196. Golay, J.; Manganini, M.; Facchinetti, V.; Gramigna, R.; Broady, R.; Borleri, G.; Rambaldi, A.; Introna, M. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003, 88, 1002–1012.
197. + T-cell-mediated immune thrombocytopenia. Blood 2016, 127, 735–738.
198. Rudnicka, D.; Oszmiana, A.; Finch, D.K.; Strickland, I.; Schofield, D.J.; Lowe, D.C.; Sleeman, M.A. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood 2013, 121, 4694–4702.
199. Stasi, R.; Del Poeta, G.; Stipa, E.; Evangelista, M.L.; Trawinska, M.M.; Cooper, N.; Amadori, S. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007, 110, 2924–2930.
200. Eisenbeis, C.F.; Grainger, A.; Fischer, B.; Baiocchi, R.A.; Carrodeguas, L.; Roychowdhury, S.; Chen, L. Combination immunotherapy of B-cell non-Hodgkin’s lymphoma with rituximab and interleukin-2: A preclinical and phase I study. Clin. Cancer Res. 2004, 10, 6101–6110.
201. Gluck, W.L.; Hurst, D.; Yuen, A.; Levine, A.M.; Dayton, M.A.; Gockerman, J.P.; Lucas, J. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res. 2004, 10, 2253–2264.
202. Stasi, R.; Pagano, A.; Stipa, E.; Amadori, S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001, 98, 952–957.
203. Chapin, J.; Lee, C.S.; Zhang, H.; Zehnder, J.L.; Bussel, J.B. Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia. Am. J. Hematol. 2016, 91, 907–911.
204. Marangon, M.; Vianelli, N.; Palandri, F.; Mazzucconi, M.G.; Santoro, C.; Barcellini, W.; Fattizzo, B.; Volpetti, S.; Lucchini, E.; Polverelli, N. et al. Rituximab in immune thrombocytopenia: Gender, age and response as predictors of long-term response. Eur. J. Haematol. 2016.
205. Reboursiere, E.; Fouques, H.; Maigne, G.; Johnson, H.; Chantepie, S.; Gac, A.C.; Reman, O.; Macro, M.; Benabed, K.; Troussard, X.; et al. Rituximab salvage therapy in adults with immune thrombocytopenia: Retrospective study on efficacy and safety profiles. Int. J. Hematol. 2016, 104, 85–91.
206. Patel, V.L.; Mahevas, M.; Lee, S.Y.; Stasi, R.; Cunningham-Rundles, S.; Godeau, B.; Kanter, J. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012, 119, 5989–5995.
207. Ghanima, W.; Khelif, A.; Waage, A.; Michel, M.; Tjonnfjord, G.E.; Romdhan, N.B.; Kahrs, J. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015, 385, 1653–1661.
208. Erickson-Miller, C.L.; DeLorme, E.; Tian, S.S.; Hopson, C.B.; Stark, K.; Giampa, L.; Valoret, E.I.; Duffy, K.J.; Luengo, J.L.; Rosen, J.; et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp. Hematol. 2005, 33, 85–93.
209. Cohn, C.S.; Bussel, J.B. Romiplostim: A second-generation thrombopoietin agonist. Drugs Today 2009, 45, 175–188.
210. Newland, A.; Godeau, B.; Priego, V.; Viallard, J.F.; Lopez Fernandez, M.F.; Orejudos, A.; Eisen, M. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: Final results from a phase 2 study. Br. J. Haematol. 2016, 172, 262–273.
211. McKenzie, C.G.; Guo, L.; Freedman, J.; Semple, J.W. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br. J. Haematol. 2013, 163, 10–23.
212. Klinger, M.H.; Jelkmann, W. Subcellular localization of thrombopoietin in human blood platelets and its release upon thrombin stimulation. Br. J. Haematol. 2001, 115, 421–427.
213. Stasi, R.; Bosworth, J.; Rhodes, E.; Shannon, M.S.; Willis, F.; Gordon-Smith, E.C. Thrombopoietic agents. Blood Rev. 2010, 24, 179–190.
214. Kapur, R.; Zufferey, A.; Boilard, E.; Semple, J.W. Nouvelle Cuisine: Platelets Served with Inflammation. J. Immunol. 2015, 194, 5579–5587.
215. Kapur, R.; Semple, J.W. The nonhemostatic immune functions of platelets. Semin. Hematol. 2016, 53, S2–S6.
216. Kapur, R.; Semple, J.W. Platelets as immune-sensing cells. Blood Adv. 2016, 1, 10–14.